Follicular lymphoma is one of the most common slow-growing (indolent) blood cancers, where abnormal B-cells accumulate mainly in lymph nodes. Most patients have a normal lifespan, but the disease typically recurs and requires multiple treatment courses over many years.
What's actually going on in research
PI3K delta inhibitors, EZH2 inhibitors, and newer CD20-bispecific antibodies are expanding options beyond standard chemo-immunotherapy. The EZH2 inhibitor tazemetostat shows specific activity in EZH2-mutated follicular lymphoma. CAR-T cell therapy and bispecific antibodies are showing strong responses in relapsed disease and may offer curative potential in some patients. Trials are also exploring fixed-duration treatment approaches to achieve durable remissions without indefinite therapy.
EZH2 inhibitor (tazemetostat)
Tazemetostat targets an epigenetic driver mutation in about 20% of follicular lymphomas, producing responses in patients with EZH2-mutated disease who have relapsed after prior therapy.
Bispecific antibodies
CD20xCD3 bispecific antibodies redirect T-cells to kill follicular lymphoma cells and are showing high response rates in relapsed disease without the complexity of CAR-T manufacturing.
CAR-T cell therapy
CAR-T cells targeting CD19 are in trials for follicular lymphoma after two or more prior therapies, with early data suggesting some patients achieve durable, possibly curative remissions.
What to know before you search
Eligibility depends on follicular lymphoma grade, tumor burden, FLIPI score, EZH2 mutation status, and prior treatment history.
What types of trials are currently open
- Treatment trials — Testing new drug combinations, targeted agents, or immunotherapy for newly diagnosed or relapsed follicular lymphoma.
- Watch-and-wait trials — Testing early treatment versus observation in asymptomatic low-tumor-burden follicular lymphoma.
- CAR-T trials — Evaluating CAR-T cell therapy in relapsed or transformed follicular lymphoma.
- Transformation trials — Testing treatment strategies when follicular lymphoma transforms to aggressive large B-cell lymphoma.
- Maintenance trials — Comparing maintenance antibody therapy versus observation after remission.
Recently added Follicular Lymphoma trials
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this study is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease.
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.
Find Follicular Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.